Albany, N.Y. – Albany Molecular Research, Inc. (NASDAQ: AMRI), a global contract research, development  and manufacturing organization that has provided services within the Life Sciences industry for more than 25 years, announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”), as well as GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

Through their joint venture, Bourne Partners (“Bourne”) has worked alongside The Carlyle Group since January 2016, advising on various pharma and pharma services investments, including the AMRI transaction. Additionally, Bourne Partners has invested in, built and advised numerous specialty pharmaceutical companies over the last decade. As advisors, investors and operators, Bourne has been involved with transactions ranging from $10 million to more than $3 billion.

Stephen H. Wise, Managing Director and Global Head of Healthcare for Carlyle, said, “Banks, Minor, Jeremy and the Bourne team worked diligently and added value in the evaluation and negotiation phases of the AMRI transaction. Their insight, experience and understanding of the CDMO and pharmaceutical sectors proved extremely useful and insightful. We also look forward to their investment and involvement alongside Carlyle in AMRI’s future growth strategy.”

Banks Bourne, Founder and Chief Executive Officer of Bourne Partners, said, “Bourne Partners was pleased to provide its expertise in the CDMO and pharma space to Carlyle in its acquisition of AMRI. We believe AMRI is an attractive, established contract services platform from which to pursue investment opportunities in the pharma services and products industry.  We look forward to providing continued advisory support to and investing alongside the Healthcare team at Carlyle. We are equally excited to begin working with the executive team at AMRI and contributing to their continued success as a preeminent CDMO.”

Credit Suisse served as exclusive financial advisor to AMRI, and Goodwin Procter LLP served as its legal advisor. Equity capital for Carlyle’s investment came from Carlyle Partners VI, and equity capital for GTCR’s investment came from GTCR Fund XI. Barclays, Bourne Partners, and Morgan Stanley & Co. LLC acted as financial advisors to Carlyle in connection with the transaction. RBC Capital Markets LLC acted as financial advisor to GTCR in connection with the transaction.

About AMRI

MRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global alternative asset manager with $170 billion of assets under management across 299 investment vehicles as of June 30, 2017. Carlyle’s purpose is to invest wisely and create value on behalf of its investors, many of whom are public pensions. Carlyle invests across four segments – Corporate Private Equity, Real Assets, Global Market Strategies and Investment Solutions – in Africa, Asia, Australia, Europe, the Middle East, North America and South America. Carlyle has expertise in various industries, including: aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media and transportation. The Carlyle Group employs more than 1,550 people in 31 offices across six continents.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Healthcare, Technology, Media & Telecommunications, Financial Services & Technology and Growth Business Services industries. The Chicago-based firm pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $12 billion in over 200 companies. For more information, please visit www.gtcr.com.